The proteasome inhibitor PSI is potently cytotoxic in vitro against human chronic myeloid leukemia (CML) and acute myeloid leukemias (AML). Here, we have tested proteasome inhibitor I (PSI) in a panel of 11 human multiple myeloma (MM) cell lines and found that it has antiproliferative activity, with an IC 50 between 4.5 and 557 nM at 48 h. PSI potentiated the toxicity of a number of chemotherapeutic agents in myeloid leukemia but not in MM cell lines, while in combination with therapeutic proteasome inhibitor PS-341 (Bortezomib) it had a synergistic effect. PSI suppressed the growth of AML cell lines more effectively than PS-341. CFU-GM colony assays revealed that CD34 þ bone marrow progenitors from CML and AML patients were more sensitive to PSI than those from normal subjects (IC 50 : 5, 15 and 50 nM for AML, CML and normal, respectively). Moreover, the growth of normal primitive progenitors (LTC-IC) was unaffected by 15 nM PSI (P ¼ 0.576). PSI-induced cell death required RNA transcription and protein synthesis, but not DNA replication, was accompanied by the upregulation of Bcl-2 and modest reduction of Bax and Bcl-X L proteins, and involved the activation of caspases 2, 3, 7 and 8. These findings lend additional support to preclinical investigations with PSI.
Introduction
The proteasome is a multiprotein complex consisting of a 20S core catalytic particle and two 19S regulatory subunits. 1 Proteins destined for degradation, after being tagged with ubiquitin, bind a receptor on the 19S subunit and enter the 20S core particle to be progressively hydrolyzed. 2 The proteasome mediates the destruction of over 80% of intracellular proteins, including those involved in growth, cell cycle and apoptosis. [3] [4] [5] [6] Suppression of protein degradation by a variety of natural and synthetic compounds that bind to and inhibit active sites within the 20S core particle have profound effects on cell proliferation and viability. 7 Proteasome inhibitors can suppress the transcriptional activity of NF-kB, preventing angiogenesis and metastasis in vivo and increasing the apoptosis of cancer cells. 8 Several compounds, including synthetic aldehydes (MG-132, PSI, lactacystin, NLVS, epoxomicin, eponemycin, TMC-95A) and boronic acids (PS-341), inhibit the proteasome by binding reversibly or irreversibly to active sites of the 20S core and display varying levels of specificity and metabolic stability. While not all cell types similarly respond to proteasome inhibition, quite invariably transformed cells are far more sensitive to proteasome blockade than normal cells 9, 10 and this sensitivity correlates with active cell proliferation. 6 Interest in the clinical development of proteasome inhibitors has arisen from recent findings on the dipeptidyl boronic acid derivative PS-341 or Bortezomib, the first such agent to progress to clinical trials. 1 Accordingly, a phase III trial is now ongoing in patients with multiple myeloma (MM) at relapse, which becomes refractory to many conventional chemotherapies. 11 The proteasome inhibitors in combination with chemotherapeutic agents or histone deacetylase inhibitors, produce synergistic effects 9, 12 that can be exploited to overcome chemoresistance in leukemic cells. Here, we report that proteasome inhibitor I (PSI) induces high level of apoptotic death and enhances the effect of cytotoxic drugs in a number of myeloid cell lines at nanomolar concentration. Multiple myeloma (MM) cell lines are also sensitive to PSI (IC 50 values ranging from 4.5 to 557 nM) although less well than acute myeloid leukemia (AML) and chronic myeloid leukemia (CML). Furthermore PSI has a strong antitumor activity, more selective against myeloid acute and chronic leukemias and with no toxicity against normal hematopoietic progenitor cells.
Materials and methods

Cells and treatments
The MM cell lines KMS12, KMS26, KMS27 and KMS34 were kindly provided by Dr T Otsuki, Kawasaki Medical School, Okayama, Japan; the cell lines RPMI 8226, IM9, HS-SULTAN, ARH 77, U266, NCI-H929 were obtained from American Type Culture Collection (ATCC), Rockville, MD, USA. The CMA-01 cell line, established in the laboratory from plasma cells derived from a patient with plasma cell leukemia, is IL-6 dependent and is maintained in medium containing 20 U/ml of human recombinant IL-6 (R&D System Inc., Minneapolis, MN, USA). The human promyelocytic and CML cell lines HL60 and K562, respectively, were obtained from Interlab Cell Line Collection (ICLC, Genova, Italy). The acute myeloid progenitor cell leukemia KG1a was from the European Collection of Animal Cell Cultures (Salisbury, UK). The CML cell lines AR230 and RWLeu4 were kindly provided by Dr S Mizutani, Tokyo, Japan and Dr MA Santucci, Bologna, Italy. The mock and Bcl-X L transfected U2OS cell line were kindly provided by Dr P Perego (INT, Milano). The cell lines were cultured in RPMI medium 1640, the MM cell lines in Icove's Modified Dulbecco's medium (IMDM) and the Bcl-X L transfected cell lines Mc Coy's medium all containing 10% fetal bovine serum (FBS) at 371C and 5% CO 2 in fully humidified atmosphere. Cells were cultured at densities ranging between 2 and 3 Â 10 5 cells/ml. CD34 selected bone marrow progenitor cells after informed consent from seven AML patients, five CML patients and from five normal donors were treated with escalating doses PSI, while three AML patients, one CML patient and four normal controls were treated with PS-341. The proteasome inhibitor peptidyl aldehyde Z-Ile-Glu(OtBu)-Ala-Leucinal (PSI) (Bachem, Swizterland) was dissolved in methanol to obtain a 10 mM stock solution that was kept at À201C. The proteasome inhibitor PS-341 or Bortezomib or VELCADE (Millenium Pharmaceuticals Inc., Cambridge, MA, USA) was dissolved in 0.9% sodium chloride salt solution to obtain a 1 mM stock solution. The cells were treated with 0.1 nM-2.5 mM PSI or PS-341 for up to 72 h. The cells were also treated with taxol (Sigma, St Louis, MO, USA), or with cisplatinum (Bristol-Myers Squibb, New York, NY, USA), or DNA (daunoblastin and ARA-C) and RNA (6-MP) interacting drugs, or inhibitors of topoisomerase I (topotecan) and II (VP16) (all from Sigma), or the bcr-abl kinase inhibitor (STI 571) (Novartis, Basel, Switzerland). In combined treatments, PSI was added to cells either simultaneously or 24 h before addition of other cytotoxic drugs. IMR90/E1A cells were plated 1 Â 10 5 cell/ml in six well/plate and 24 h after plating cells were treated with MG-132 (2.5 mM), PSI (10 nM) and etoposide (50 mM). Cells were collected after 24 h of treatment and the Trypan blue assay was performed to determine the percentage of cell death.
Single and combined cytotoxicity assays
Cytotoxicity analysis on cell lines and bone marrow samples was performed by the WST-1 colorimetric assay (Boehringer Mannheim GmbH, Germany). 13 Briefly, 10 ml of WST-1 were added to each of the 96-well culture plates containing 100 ml of cell suspension. After 4 h incubation at 371C, plates were evaluated by means of 1420 VICTOR multilabel counter (EG&G Wallac, Finland) and data expressed as mean percentage of three replicates normalized to the untreated control.
The effect of the combination of PSI (A) with other drugs (B) was evaluated according to the method of Kern et al.
14 An R index of 1 (additive effect) or lower indicated the absence of synergism. Synergism was defined as any value of R41. 15 
Flow cytometric apoptosis and cell cycle analysis
The effect PSI on cell cycle was evaluated on cells cultured for up to 72 h with escalating doses of PSI, fixed in 70% ethanol, treated with 0.5 mg/ml. RNaseA (Sigma) in PBS plus 0.1% saponin and incubated at 371C for 30 min, stained with 20 mg/ml propidium iodide (Sigma), and analyzed for DNA content with a FACSCalibur flow cytometer (Becton Dickinson, San Josè, CA, USA). The acquired histograms were analyzed by ModFit LTt software (Verity Software House, Topshan, ME, USA) to determine the cell cycle phases. HL60 cells were pretreated for 3 or 16 h with previously determined noncytotoxic doses of the protein synthesis inhibitor cycloheximide (1 mg/ml) (Sigma) or the RNA transcription inhibitor actinomycin D (5 ng/ml) (Sigma) or the DNA polymerase inhibitor (0.1 mg/ml) (Sigma) and then exposed for further 24 h to PSI 1 and 10 nM. Samples cultured with the single agents only were included as controls. Hypodiploid, apoptotic cells were detected by flow cytometry after propidium iodide staining, as described above.
Western blot determinations
Cell pellets were lysed in Laemmly buffer (0.125 M. Tris-HCl, pH 6.8, 5% SDS) containing a protease plus phosphatase inhibitors 1 mM PMSF, 10 mg/ml pepstatine, 100 KIU/ml aprotinin, 10 mg/ml leupeptin (all from Calbiochem, La Jolla, CA, USA) and 1 mM sodium orthovanadate (Sigma). The lysates were boiled for 2 min, sonicated and quantitated by the micro-BCA method (Pierce, Rockford, IL, USA). Aliquots containing 40 mg/ml of protein were loaded on 12 or 7% SDS-PAGE, size-fractionated and electroblotted onto PVDF membranes (Millipore, Bedford, MA, USA). After blocking with 5% nonfat dried milk in PBS plus 0.1% Tween (Sigma), the membranes were incubated with appropriate dilutions (1:800-1:1500) of primary antibody and after extensive washing, with 1:4000 dilution of the peroxidase-labelled secondary antibody, washed again and revealed by ECL super signal (Pierce) and autoradiography. The reagents used were monoclonal antibodies to Bcl-2, rabbit antibodies to Bax and Bcl-X L (Pharmingen, San Diego, CA, USA). To normalize for protein content, blots were reprobed with rabbit antibodies to b-actin (Sigma). Western blots to analyze caspase processing were performed on IMR90/E1A cells. Cellular lysates were collected after 24 h of treatment in Laemmly Sample Buffer. Western Blot analysis was performed using anticaspase2, anticaspase-7 (Cell Signalling, Beverly, MA, USA), anticaspase-8 (Alexis, Lausen, Switzerland), anti-p85PARP (Promega, Madison, WI, USA), antitubulin antibodies.
Measurement of caspase-3/7 activity
IMR90/E1A cells were plated (0.75 Â 10 5 cells/ml) in a 96-well plate 24 h before treatment for 24 h at 371C. Homogeneous caspase-3/7 (100 ml) reagent was then added to each well and after 50 min of incubation the fluorescence of each well was measured at Ex 485 Em 525 using a microplate spectrofluorometer.
Immuno-magnetic separation of CD34
þ cells and clonogenic assays Low-density mononuclear cells (LD-MNC) were separated from bone marrow aspirates by Ficoll-Paque gradient (Nycomed Pharma AS, Oslo, Norway) centrifugation. The recovered cells were then washed twice in Hanks' balanced salt solution (HBSS) and resuspended in IMDM 10% FBS. To isolate the CD34 þ cells, the LD-MNC were incubated for 15 min at 41C with an anti-CD34 monoclonal antibody, then washed and incubated for 15 min at 41C with anti-mouse immuno-magnetic beads (Miltenyi Biotec, Bergisch Gladbach, Germany). For the flow cytometry analysis, CD34-phycoerythrin conjugated antibody (HPCA-2, Becton Dickinson) was added to the cells for 15 min at 41C. Viability and purity of separated cells were assessed by Trypan blue dye exclusion and flow cytometry analysis, respectively. For CFU-GM clonogenic assays, 5 Â 10 3 /ml CD34 þ cells were plated in a methylcellulose culture medium (MethoCult 4434, StemCell Technologies Inc., Vancouver, Canada) containing 0.9% methylcellulose in Iscove's MDM, 30% fetal bovine serum, 1% bovine serum albumin, 10 À4 M 2-Mercaptoethanol, 2 mM L-glutamine, 50 ng/ml rhSCF, 10 ng/ml rhGM-CSF, 10 ng/ml rhIL-3, 3 U/ml rhEPO with different doses of PSI or PS-341. Triplicate dishes were incubated at 371C in a 5% CO 2 fully humidified atmosphere for 14 days. The aggregates of X40 and o40 cells were, respectively, scored as colonies and clusters.
To determine the frequencies of long-term culture initiating cells (LTC-IC), 16 a limiting dilution assay (LDA) 17 was performed
Effect of PSI on multiple myeloma and myeloid leukemiason LD-MNC from three normal subjects. LD-MNC were treated for 24 h and then were seeded on the inactivated M2-10B4 murine cell line in 96-well microtiter plates. The dilution steps (16 replicates for each dilution) were 3000, 6000, 9000, 12 000 and 15 000 cells/well in 200 ml/well of LTBMC medium (MyeloCult H5100, StemCells). After 5 weeks of culture at 331C with 5% CO 2 , the adherent and nonadherent cells were harvested and, to evaluate colony formation, the cells from each well were plated in 24-well plates in 250 ml of colony assay semisolid medium (MethoCult 4434, StemCells) as described for clonogenic assays. The number of negative wells was then determined, and the frequency of LTC-IC evaluated by means of Poisson statistics. 18 
Results
Effects of PSI and PS-341 on human MM and ML cell lines
We previously showed that nanomolar concentrations of PSI are highly cytotoxic in vitro against human myeloid leukemic cell lines. 9 In the present study, we asked whether MM cells, which are remarkably sensitive to the proteasome inhibitor PS-341, 19, 20 are equally sensitive to PSI. Of a panel of 11 MM cell lines tested in time-and dose-dependent assays (Table 1a) CMA01, U266 and H929 cells were, already at 24 h, the most sensitive to PSI. KMS12, KMS26, KMS27 and KMS34 showed an intermediate sensitivity, whereas RPMI 8226, IM9, SULTAN and ARH77 cells were the least sensitive (IC 50 ranging between 95 and 470 at 72 h). In accordance with our previous findings, 9 PSI was highly cytotoxic on HL60, KG1a, RWLeu4 and AR230, and far less on K562 (Table 1b) . When the effect of PSI in these cells was compared with PS-341, the former inhibitor resulted more toxic on the AMLs (KG1a and HL60) while the latter was more toxic, at least after 24 h treatment, on CMLs (K562, RWLeu4 and AR230) (Table 1b) .
Effects of PSI in combination with other chemotherapeutic agents
As PSI enhances the cytotoxicity of the anticancer drugs cisplatinum and taxol in HL60 cells, 9 we extended this analysis to other cell lines. No increased cytotoxicity was seen when PSI was simultaneously added together with any of the following drug concentrations: 1-500 ng/ml cisplatinum, 1-100 nM taxol, 1-20 mM daunoblastin, 1-20 mM ARA-C, 1-50 mM VP16, 1-100 mM 6MP, 1-50 nM topotecan, 0.01-1 mM STI 571. However, when these drugs were added 24 h after treatment with 1-10 nM PSI, a synergistic effect with 1 mM daunoblastin was seen only in AR230 cells (data not shown). As expected from previous experiments, 9 an additive effect with taxol (PSI 1 nM and taxol 10 nM) and a synergistic effect with cisplatinum was seen only in HL60 (PSI 1 nM and cisplatinum 100 ng/ml). Daunoblastin and melphalan, the most effective drugs in vitro and in vivo against MM, 21 did not potentiate the activity of PSI in any of the MM cell lines. Furthermore, when 5 nM PSI and 20 nM PS-341 were administrated simultaneously on K562, a synergistic effect was observed (R Kern index, respectively, of 1.56 at 24 h, 1.8 at 48 h and 1.6 at 72 h (Figure 1) ).
Effect of PSI and PS-341 on normal and leukemic progenitor cells
To determine the effect of PSI and PS-341 on fresh human normal and leukemic progenitors, immunoselected CD34 þ bone marrow cells from AML and CML patients and from normal donors were assayed for CFU-GM formation after treatment with these inhibitors. A dose-dependent suppression of CFU-GM colony growth was observed in all cases (Figure 2a  and b) . Remarkably, however, PSI suppressed the clonogenic potential of AML and CML (IC 50 : 5 nM and 15 nM, respectively) more than normal bone marrow progenitors (IC 50 of 50 nM) (Student's t-test Po0.001) (Figure 2a) . On the other hand, PS-341 more effectively inhibited the clonogenic potential of CML (IC 50 : 6.8 nM) and normal bone marrow (IC 50 : 11.3 nM) than AML progenitors (IC 50 : 46.8 nM) (Figure 2b) .
To investigate the effect of PSI on primitive hematopoietic progenitors, LTC-IC culture assays were performed on three normal bone marrow samples with or without 15 nM PSI. As the mean LTC-IC frequency/10 6 seeded cells accounted for 2067107 and 2037105 in the absence or presence of PSI, Effect of PSI on multiple myeloma and myeloid leukemias F Servida et al respectively, (P ¼ 0.576) (Figure 2c) , the results underscore the poor sensitivity of normal primitive hemopoietic progenitors to PSI.
Cell cycle analysis of PSI treated cell lines
DNA flow cytometric analyses were performed to investigate if PSI, like other proteasome inhibitors, inhibits cell cycle progression. 6, 22 A decrease of G 1 and an accumulation of G 2 phase cells were seen in RWLeu4 and Raji cells (Table 2) , especially 48 h after treatment with 10 nM PSI. In AR230 cells instead, a marked decrease in S and rise in G 2 /M phase fraction was seen, while in HL60 only a slight increase in S-phase was observed in response to 10 nM PSI. No alterations of the cell cycle phases were seen after incubation with 1 nM PSI.
Mechanisms of PSI-induced apoptosis
To determine the mechanisms of PSI-induced cell death, we firstly examined the effect of not cytotoxic doses of aphidicholin, Effect of PSI on multiple myeloma and myeloid leukemias F Servida et al actinomycin D and cycloheximide, inhibitors of DNA synthesis, RNA transcription and protein synthesis, respectively. We found that whereas aphidicholin was ineffective, actinomycin D and cycloheximide potently inhibited the cytotoxicity of PSI (Figure 3 ), thus indicating that PSI-induced cell death requires active protein synthesis and transcription. We have previously shown that enforced expression of Bcl-2, but not inactivation of p53, antagonizes the cytotoxic activity of PSI, suggesting a Bcl-2-dependent and p53-independent mechanism of PSI-induced cell death. 9 To further extend these observations, we examined the dose-and time-dependent cytotoxic effects of PSI in cells overexpressing the antiapoptotic gene Bcl-X L . In contrast to mock cells, which were highly sensitive to PSI (IC 50 10 nM) (Figure 4a ), Bcl-X L overexpressing cells were quite resistant (IC 50 41000 nM at 24 h), thus indicating a Bcl-X L dependence of PSI-induced cell death.
As cell death often involves the reciprocal regulation of the proapoptotic protein Bax and of the antiapoptotic proteins Bcl-2 and Bcl-X L , 6, 23, 24 we analyzed the expression of these proteins following treatment with PSI in ARH77 and CMA01, respectively, resistant and sensitive to PSI (see above). The constitutive levels of Bcl-2, Bcl-X L and Bax differed among these cells, with Bax levels being in CMA01 3.3-fold higher than in ARH77 (Figure 4b) . After 48 h of treatment with PSI, Bcl-2 increased in both ARH77 and CMA01, whereas Bax slightly decreased in the latter. The levels of Bcl-X L modestly declined in both cell lines (Figure 4b) .
To determine the involvement of caspases in PSI-induced cell death, we used IMR90 fibroblasts stably expressing the E1A oncogene (IMR90/E1A cells) and HL60 cell line. Proteasome inhibitors efficiently induced cell death in 40-50% of the cells compared to a known apoptotic inducer such as etoposide (Figure 5a ). Apoptosis induced by PSI were shown by measuring the activity of caspase-3 and -7 with a fluorometric substrate cleavage assay (Figure 5b ). Processing of caspase-2, -8 and -7 was next investigated by immunoblotting in the IMR90/E1A cell line and in the AML cell line HL60 (Figure 5c and d) . Both caspase-2 and -8 initiator caspases are processed to the respective cleaved forms in response to proteasome inhibitors and etoposide. MG-132 and PSI also induced a significant processing of the effector caspase-7 as shown by the appearance of the p20 cleaved form. Proteasome inhibitors significantly induce cleavage of PARP, a well-defined substrate for caspase-3 and -7. Thus PSI induces activation of caspase-2, 8, 7 and 3, as in the case of etoposide and of MG-132, another proteasome inhibitor.
Discussion
Proteasome-dependent protein destruction is crucial for the maintenance of cellular homeostasis and impairment of this process can lead to a wide range of human diseases, including neurodegenerative disorders and cancer. 25, 26 As a result of its key metabolic function, inhibition of the proteasome by a variety of compounds almost invariably results in growth arrest and apoptotic cell death. 1 While the growth arrest most likely arises from the stabilization of the tumor suppressor protein p53 and of the CDK inhibitors p21waf1 and p27, 27, 28 the apoptosis is thought to arise from the accumulation of incompatible regulatory proteins triggering the activation of a caspase-3-and -8-dependent events. 29 Interestingly, proteasome inhibitors can hypersensitize or kill tumor cells that are intrinsically resistant to conventional chemotherapy, 30 thus regarding the proteasome as Effects of RNA transcription and protein synthesis inhibition on PSI-induced cell death. HL60 cells were treated for 24 h with not cytotoxic concentrations of actinomycin D and cycloheximide, inhibitors of RNA transcription and protein synthesis, respectively, in combination with PSI. Subdiploid, apoptotic cells were detected by DNA flow cytometry after staining with propidium iodide. In all, 10 000 events per histogram were analyzed (horizontal axis linear fluorescence intensity, vertical axis relative cell number).
Effect of PSI on multiple myeloma and myeloid leukemias F Servida et al a key target for cancer therapy. Several natural and synthetic inhibitors of the proteasome are being investigated for their in vivo activity in preclinical studies. One of these, the dipeptide boronic acid derivative PS-341, displays cytotoxic activity against MM, lymphoma, prostate, breast, lung, pancreatic, ovarian, colon and bladder cancer, 25, [31] [32] [33] [34] [35] potentiates apoptosis by anticancer agents by preventing IkB degradation and activation of NF-kB, 25, 11 and possesses antiangiogenic effects associated with inhibition of vascular endothelial growth factor (VEGF) secretion. 36 PS-341 is the first proteasome inhibitor to enter clinical trials in patients with MM, lung and renal cancer. 31, 37 We have previously reported that PSI is quite effective in vitro in killing myeloid leukemias at nanomolar doses, 38 in contrast to other proteasome inhibitors effective at micromolar doses. 39 Here, we have analyzed and compared the toxicity of PSI in MM to that of PS-341, to which these cells are particularly sensitive. 19, 20 Although the MM cells tested showed a variable time-and dose-dependent cytotoxicity to PSI, nonetheless this effect occurred at nanomolar concentrations (IC 50 values ranging between 4.5 and 557 nM at 48 h), indicating that PSI is almost as potent in MM as in AML or CML cells. PS-341 was more cytotoxic against most of the MM tested and more effective than PSI, at least after 24 h treatment, on CML cell lines (K562, AR230 and RWLeu4) but not on AML cell lines (KG1a and HL60).
The main side-effect of antineoplastic drugs is myelotoxicity. 25, 40 To determine the cytotoxic effect of PSI and PS-341 on hemopoietic bone marrow progenitors, we performed after the treatment with each proteasome inhibitor CFU-GM assays on immunomagnetically purified CD34 þ cells. Progenitor cells from AML and CML patients were more sensitive to PSI than normal donors (IC 50 : 5, 15 and 50 nM, respectively), while PS-341, which is more effective than PSI on CML patients, Effect of PSI on multiple myeloma and myeloid leukemias F Servida et al was statistically more toxic on normal hemopoietic progenitor cells (IC 50 : 6.8 and 11.3 nM, respectively). Furthermore, we have demonstrated that the growth of more immature hematopoietic progenitors, as determined by LTC-IC assays, is not at all affected by 15 nM PSI. Collectively, these results suggest that neoplastic hemopoietic progenitors are more sensitive to PSI (but not to PS-341) than normal progenitors, a finding which underscores a potential therapeutic window for PSI.
In our study, PSI enhanced in few cases the cytotoxicity of the individual chemotherapeutic drugs taxol, cisplatinum and daunoblastin, but only when the latter were administered 24 h after PSI, and this chemosensitizing activity could be seen in AML and CML, but not in MM cells. At variance with results, PS-341 has been shown to chemosensitize MM cells to anticancer drugs, including melphalan and doxorubicin, with the most pronounced synergy seen when cells are pretreated with the anticancer drugs prior to PS-341. 30 Furthermore the simultaneous treatment with PSI and PS-341 on the CML cell line K562 resulted in a synergistic effect. These findings could reflect a different mechanism of action of PSI and PS-341, although we have no evidence to prove this.
We have shown that PSI-induced cell death can be blocked by protein synthesis and RNA transcription inhibitors, but not by DNA synthesis inhibitors, leading to conclude that for its activity PSI requires de novo protein and RNA synthesis. We have additionally shown that Bcl-X L overexpression antagonizes PSI-induced cell death, and since Bcl-2 overexpression has a similar effect, 9 these findings highlight the Bcl-2-and Bcl-X L -dependence of PSI-induced cell death.
To determine whether PSI-induces cell death in MM cell lines involves a reciprocal regulation of Bcl-2 and its family members Bcl-X L and Bax, we monitored the levels of these proteins after treatment. In agreement with other reports, 41, 42 we have found minor changes in the levels of the proapoptotic Bax and the antiapoptotic Bcl-X L after PSI treatment. However, PSI induced the accumulation of the antiapoptotic protein Bcl-2 in MM cells, similar to what we had observed previously in myeloid cells. 9 This upregulation of Bcl-2, likely reflecting a block in Bcl-2 degradation physiologically accomplished by the proteasome, 23 is seen also in response to treatments with PS-341. 43 The unexpected upregulation of Bcl-2, which should favor survival, is in apparent contrast with the potent death-inducing activity of PSI and suggest that, since survival depends on the overall balance between pro-and antiapoptotic factors, other PSIresponsive components of the apoptotic pathway may have a key role in tilting the balance towards apoptosis. In the case of PS-341, the dramatic upregulation of the BH3-only protein Noxa in the face of Bcl-2 accumulation 43 is the key event for apoptosis.
We and others have provided evidence that PSI kills cells by an apoptotic mechanism involving the activation of caspases, 9, 6, 44 which emphasizes the link between ubiquitinproteasome pathways and apoptosis. We have shown that caspase-2, 3, 7 and 8 are activated during PSI-induced apoptosis. Further studies will be required to determine whether PSI induces cell death thorough the activation of the intrinsic/ mitochondrial or the extrinsic pathway.
By altering the orderly and temporal turnover of cell cycle regulatory molecules, proteasome inhibitors can affect cell cycle progression. 6, 4, 41, 22 In accordance with this, we have found that PSI could induce a G 2 -M phase arrest in the myeloid leukemia RWLeu4 and in the Burkitt's lymphoma cell line Raji, but not in the MM cell lines. Although the underlying mechanism for such phase arrest is unclear, the finding nevertheless indicates that this response to PSI is not a general, but rather dependent on the genetic abnormalities of the cells.
In conclusion, we have shown that MM, CML and AML cells can be killed in vitro by nanomolar concentrations of PSI and that normal bone marrow progenitor cells are less sensitive than those from CML and AML derived progenitors, establishing a therapeutic window. PSI, in addition, can sensitize CML and AML, but not MM, to chemotherapeutic agents. These findings further support studies to determine the toxicity and anticancer properties of PSI in animal models.
